L. reuteri FN041 from Human Milk Ameliorates Colitis via Microbiota Modulation

Study Background and Research Question

Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by persistent inflammation of the colon and rectum and currently affects over 5 million individuals worldwide. Although advances in UC treatment have reduced disease burden, high relapse rates and the need for surgery in refractory cases persist. Growing evidence implicates gut microbiota dysbiosis and metabolite alteration as key factors in UC pathogenesis and severity. Consequently, the use of probiotics to restore gut microbial balance and modulate immune responses has become a focus of translational research. However, the specific efficacy and mechanistic basis of individual probiotic strains in UC models remain incompletely understood. The study by Luo et al. (Food Bioscience, 2025) addresses this gap by investigating whether Limosilactobacillus reuteri FN041, a probiotic strain isolated from human milk, can prevent or ameliorate DSS-induced colitis in mice through modulation of gut microbiota and metabolites.

Key Innovation from the Reference Study

The principal innovation of this research lies in the identification and mechanistic characterization of L. reuteri FN041's ability to attenuate colitis beyond symptom suppression. Unlike previous probiotic studies that focused primarily on clinical endpoints or broad microbial shifts, Luo et al. employed integrated metagenomic and metabolomic approaches to directly link probiotic-induced changes in specific gut bacterial populations and metabolites with reduced colitis severity. By demonstrating that restoration of beneficial bacteria and correction of metabolite disruptions are central to the therapeutic effect, the paper provides a detailed systems-level view of how targeted probiotics can restore intestinal homeostasis in inflammatory disease models (internal summary).

Methods and Experimental Design Insights

The authors used a robust murine model of UC induced by dextran sodium sulfate (DSS), which reliably recapitulates key features of human colitis, including mucosal inflammation, epithelial barrier dysfunction, and altered immune signaling. Mice were administered human milk-derived L. reuteri FN041 orally during DSS exposure and compared to vehicle controls. Disease progression was assessed via standard indices: body weight loss, colon length, Disease Activity Index (DAI), and histological scoring. To dissect mechanisms, the study employed:

• Quantification of inflammatory cytokines (IL-6, IL-10) and oxidative stress markers (malondialdehyde, MDA) in serum and colon tissue.
• Evaluation of intestinal barrier integrity by measuring tight junction protein expression and serum markers of permeability (lipopolysaccharide, D-lactate).
• High-throughput metagenomic sequencing of fecal samples to profile gut microbiota diversity and composition.
• Untargeted metabolomics of cecal contents to identify metabolite shifts associated with colitis and probiotic treatment.
• Correlation analyses integrating clinical, microbial, and metabolite data to pinpoint interdependent changes.

This multi-modal design enabled rigorous attribution of observed therapeutic effects to specific biological processes modulated by L. reuteri FN041.

Core Findings and Why They Matter

L. reuteri FN041 treatment led to pronounced alleviation of DSS-induced colitis symptoms, as evidenced by reduced weight loss, less colon shortening, and lower DAI and histological scores compared to controls (reference study). Key mechanistic findings include:

• Reduced Inflammation and Oxidative Stress: Probiotic administration decreased local and systemic IL-6, increased anti-inflammatory IL-10, and reduced MDA in colon tissue, indicating both local and systemic immunomodulation.
• Restoration of Barrier Function: Increased expression of tight junction proteins and reduced serum levels of lipopolysaccharide and D-lactate suggest improved epithelial integrity and reduced gut permeability.
• Microbiota Remodeling: Metagenomic analysis revealed increased abundance of beneficial commensals and a decrease in bacteria linked to inflammation and tissue damage. Microbial diversity, often depleted in UC, was partially restored.
• Metabolite Correction: Metabolomic profiling identified several key metabolites—such as 1-myristoyl-sn-glycero-3-phosphocholine and gamma-L-glutamylputrescine—disrupted by DSS and partially normalized by L. reuteri FN041, linking metabolic restoration to disease improvement.
• Systems Integration: Correlation analyses confirmed that clinical improvement, microbial shifts, and metabolite changes were tightly interdependent, supporting a holistic model of probiotic action.

Collectively, these findings advance the understanding of how specific probiotics can orchestrate multi-layered biological effects to counteract UC pathology.

Comparison with Existing Internal Articles

The mechanistic insights from Luo et al. resonate with recent research emphasizing the centrality of the gut microbiota-metabolite axis in intestinal inflammation. For example, the internal article "Human Milk L. reuteri FN041 Alleviates Colitis via Microbiota Modulation" provides a complementary overview of how targeted probiotic interventions can help restore intestinal homeostasis in colitis models, reinforcing the external study's conclusions. Moreover, the methodology of monitoring protein concentration changes during gut barrier assessment aligns with molecular biology workflows described in "BCA Protein Assay Kit: Precision Bicinchoninic Acid Protein Quantification", which underscores the importance of sensitive protein quantification assays in tracking disease markers and cellular responses. Both resources highlight the utility of precise biochemical tools in dissecting complex host-microbe interactions.

Limitations and Transferability

While the multi-omics approach and thorough phenotypic characterization are strengths, certain limitations should be noted. The study was conducted in a murine DSS-colitis model, which, though widely used, does not capture all aspects of human UC pathology. The effects of L. reuteri FN041 were characterized in an acute setting; chronic and relapsing models are needed to assess long-term efficacy and safety. The generalizability to genetically diverse host backgrounds or established UC patient populations is not directly addressed. Furthermore, while correlations between microbiota, metabolites, and clinical outcomes are strong, causal pathways would benefit from targeted intervention or knockout studies. Nevertheless, the translational potential is high given the strain's origin in human milk and its demonstrated pleiotropic benefits.

Protocol Parameters

• DSS induction: 2–3% DSS in drinking water for 5–7 days to induce colitis in mice; adjust concentration and duration based on animal strain and tolerance.
• Probiotic administration: Oral gavage of L. reuteri FN041 (typically 1×10⁹ CFU/mouse/day); start 1–2 days prior to DSS exposure and continue throughout the induction period.
• Protein concentration measurement: Use a sensitive protein assay for quantification of tight junction proteins and cytokines in colon tissue lysates; sample volumes of 1–20 μL are compatible with most standard colorimetric assays.
• Metagenomic and metabolomic profiling: Collect fecal and cecal content at defined time points; use high-throughput sequencing and LC-MS for comprehensive analysis.
• Barrier function assessment: Measure serum D-lactate and lipopolysaccharide as indicators of intestinal permeability; validate with immunostaining for tight junction proteins.

Research Support Resources

To accurately measure protein concentration changes in intestinal tissue lysates and support tight junction analysis, researchers may utilize the BCA Protein Assay Kit (SKU K4101) from APExBIO. This bicinchoninic acid protein quantification approach offers high sensitivity (detection limit 0.5 μg) and linearity (50–2000 μg/mL), making it well-suited for studies focusing on protein detection in cell lysates and molecular markers of barrier function. By integrating such tools within multi-omics colitis research workflows, investigators can achieve precise, reproducible biochemical profiling to complement metagenomic and metabolomic analyses.